Dose-Expansion Study of Low Dose Post-Transplant Cyclophosphamide/Tacrolimus/Ruxolitinib for Graft-versus-Host Disease (GVHD) Prophylaxis in Myeloablative Allogeneic Peripheral Blood Stem Cell Transplantation

Abroad (travel likely)RecruitingPHASE2

Conditions

Leukemia · Myelodysplasia · Chronic Myelomonocytic Leukemia

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
Contact: Study coordinator (Hannah K Choe, MD) · Hannah.Choe@osumc.edu
Contact: Principal Investigator (Hannah K Choe, MD)

Study leads

Hannah Choe, MD
Principal Investigator
Ohio State University Comprehensive Cancer Center

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

ABBA CORD: dCBT w/ Abatacept for aGVHD Prophylaxis

Acute Myelogenous Leukemia · Acute Lymphatic Leukemia · Chronic Myelogenous Leukemia

Abroad (travel likely)RecruitingPHASE2

Cleveland, United States

Improving Communication and Building a Stronger Medical Home Among Spanish-speaking Families

Leukemia · Non Hodgkin Lymphoma

Abroad (travel likely)Recruiting

Aurora, United States

Comparison of Intralipid With SMOF Lipid Following HSCT

Leukemia · HSCT

Abroad (travel likely)Recruiting

Tehran, Iran

Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms

Acute Myeloid Leukemia · Essential Thrombocythemia · Myelodysplastic Syndrome

Abroad (travel likely)RecruitingPHASE2

Seattle, United States